|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman
PA, et al: Trastuzumab plus adjuvant chemotherapy for operable
HER2-positive breast cancer. N Engl J Med. 353:1673–1684.
2005.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ruggiero AM, Liu Y, Vidensky S, Maier S,
Jung E, Farhan H, Robinson MB, Sitte HH and Rothstein JD: The
endoplasmic reticulum exit of glutamate transporter is regulated by
the inducible mammalian Yip6b/GTRAP3-18 protein. J Biol Chem.
283:6175–6183. 2008.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Doly S and Marullo S: Gatekeepers
controlling GPCR export and function. Trends Pharmacol Sci.
36:636–644. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Doly S, Shirvani H, Gäta G, Meye FJ,
Emerit MB, Enslen H, Achour L, Pardo-Lopez L, Yang SK, Armand V, et
al: GABAB receptor cell-surface export is controlled by an
endoplasmic reticulum gatekeeper. Mol Psychiatry. 21:480–490.
2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Fo CS, Coleman CS, Wallick CJ, Vine AL and
Bachmann AS: Genomic organization, expression profile, and
characterization of the new protein PRA1 domain family, member 2
(PRAF2). Gene. 371:154–165. 2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kim JT, Cho MY, Choi SC, Kim JW, Chae SK,
Yoon DY, Kim JW and Lim JS: Prenylated Rab acceptor 1 (PRA1)
inhibits TCF/beta-catenin signaling by binding to beta-catenin.
Biochem Biophys Res Commun. 349:200–208. 2006.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chen Y, Huang Y, Huang Y, Xia X, Zhang J,
Zhou Y, Tan Y, He S, Qiang F, Li A, et al: JWA suppresses tumor
angiogenesis via Sp1-activated matrix metalloproteinase-2 and its
prognostic significance in human gastric cancer. Carcinogenesis.
35:442–451. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bai J, Zhang J, Wu J, Shen L, Zeng J, Ding
J, Wu Y, Gong Z, Li A, Xu S, et al: JWA regulates melanoma
metastasis by integrin alphaVbeta3 signaling. Oncogene.
29:1227–1237. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chen H, Bai J, Ye J, Liu Z, Chen R, Mao W,
Li A and Zhou J: JWA as a functional molecule to regulate cancer
cells migration via MAPK cascades and F-actin cytoskeleton. Cell
Signal. 19:1315–1327. 2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Geerts D, Wallick CJ, Koomoa DL, Koster J,
Versteeg R, Go RC and Bachmann AS: Expression of prenylated Rab
acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma:
Correlation with clinical features, cellular localization, and
cerulenin-mediated apoptosis regulation. Clin Cancer Res.
13:6312–6319. 2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Brodeur GM, Seeger RC, Schwab M, Varmus HE
and Bishop JM: Amplification of N-myc in untreated human
neuroblastomas correlates with advanced disease stage. Science.
224:1121–1124. 1984.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yco LP, Geerts D, Koster J and Bachmann
AS: PRAF2 stimulates cell proliferation and migration and predicts
poor prognosis in neuroblastoma. Int J Oncol. 42:1408–1416.
2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Borsics T, Lundberg E, Geerts D, Koomoa
DL, Koster J, Wester K and Bachmann AS: Subcellular distribution
and expression of prenylated Rab acceptor 1 domain family, member 2
(PRAF2) in malignant glioma: Influence on cell survival and
migration. Cancer Sci. 101:1624–1631. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wang CH, Liu LL, Liao DZ, Zhang MF, Fu J,
Lu SX, Chen SL, Wang H, Cai SH, Zhang CZ, et al: PRAF2 expression
indicates unfavorable clinical outcome in hepatocellular carcinoma.
Cancer Manag Res. 10:2241–2248. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Qian Z, Wei B, Zhou Y, Wang Q, Wang J, Sun
Y, Gao Y and Chen X: PRAF2 overexpression predicts poor prognosis
and promotes tumorigenesis in esophageal squamous cell carcinoma.
BMC Cancer. 19(585)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chen X, Feng J, Ge Z, Chen H, Ding W, Zhu
W, Tang X, Chen Y, Tan Y and Ma T: Effects of the JWA gene in the
regulation of human breast cancer cells. Mol Med Rep. 11:3848–3853.
2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Xu L, Cheng L, Yang F, Pei B, Liu X, Zhou
J, Zhu Y and Wang S: JWA suppresses the invasion of human breast
carcinoma cells by downregulating the expression of CXCR4. Mol Med
Rep. 17:8137–8144. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta DeltaC(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658.
2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Cancer Genome Atlas Research Network.
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Grebić D, Pirjavec A, Kustić D and Klarica
Gembić T: Surgical treatment for breast cancer and axillary
metastases: Historical perspective. Acta Med Hist Adriat.
19:125–136. 2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Maughan KL, Lutterbie MA and Ham PS:
Treatment of breast cancer. Am Fam Physician. 81:1339–1346.
2010.PubMed/NCBI
|
|
26
|
Pagani O, Senkus E, Wood W, Colleoni M,
Cufer T, Kyriakides S, Costa A, Winer EP and Cardoso F: ESO-MBC
Task Force. International guidelines for management of metastatic
breast cancer: Can metastatic breast cancer be cured? J Natl Cancer
Inst. 102:456–463. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Cardoso F, Kyriakides S, Ohno S,
Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S and Senkus E:
ESMO Guidelines Committee. Early breast cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 30:1194–1220. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kuchenbaecker KB, Hopper JL, Barnes DR,
Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE,
Milne RL, Andrieu N, et al: Risks of breast, ovarian, and
contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
JAMA. 317:2402–2416. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kouno J, Nagai H, Nagahata T, Onda M,
Yamaguchi H, Adachi K, Takahashi H, Teramoto A and Emi M:
Up-regulation of CC chemokine, CCL3L1, and receptors, CCR3, CCR5 in
human glioblastoma that promotes cell growth. J Neurooncol.
70:301–307. 2004.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Roos WP, Thomas AD and Kaina B: DNA damage
and the balance between survival and death in cancer biology. Nat
Rev Cancer. 16:20–33. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Spill F, Reynolds DS, Kamm RD and Zaman
MH: Impact of the physical microenvironment on tumor progression
and metastasis. Curr Opin Biotechnol. 40:41–48. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wan L, Pantel K and Kang Y: Tumor
metastasis: Moving new biological insights into the clinic. Nat
Med. 19:1450–1464. 2013.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kozłowski J, Kozłowska A and Kocki J:
Breast cancer metastasis-insight into selected molecular mechanisms
of the phenomenon. Postepy Hig Med Dosw (Online). 69:447–451.
2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Schweneker M, Bachmann AS and Moelling K:
JM4 is a four-transmembrane protein binding to the CCR5 receptor.
FEBS Lett. 579:1751–1758. 2005.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Lu J, Tang Y, Farshidpour M, Cheng Y,
Zhang G, Jafarnejad SM, Yip A, Martinka M, Dong Z, Zhou J, et al:
JWA inhibits melanoma angiogenesis by suppressing ILK signaling and
is an independent prognostic biomarker for melanoma.
Carcinogenesis. 34:2778–2788. 2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, Wu
C, Wang C and Ye L: Wnt/β-catenin signaling in cancers and targeted
therapies. Signal Transduct Target Ther. 6(307)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang
X, Zhou Z, Shu G and Yin G: Wnt/β-catenin signalling: function,
biological mechanisms, and therapeutic opportunities. Signal
Transduct Target Ther. 7(3)2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
He W, Tang J, Li W, Li Y, Mei Y, He L,
Zhong K and Xu R: Mutual regulation of JAG2 and PRAF2 promotes
migration and invasion of colorectal cancer cells uncoupled from
epithelial-mesenchymal transition. Cancer Cell Int.
19(160)2019.PubMed/NCBI View Article : Google Scholar
|
